These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1419818)
1. Low-dose etoposide: a potential therapy for myelodysplastic syndromes. Ogata K; Yamada T; Ito T; Gomi S; Tanabe Y; Ohki I; Dan K; Nomura T Br J Haematol; 1992 Oct; 82(2):354-7. PubMed ID: 1419818 [TBL] [Abstract][Full Text] [Related]
2. Application of low-dose etoposide therapy for myelodysplastic syndromes. Ogata K; Nomura T Leuk Lymphoma; 1993 Dec; 12(1-2):35-9. PubMed ID: 8161935 [TBL] [Abstract][Full Text] [Related]
3. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b. Aul C; Gattermann N; Schneider W Eur J Haematol; 1991 Jan; 46(1):11-6. PubMed ID: 1988303 [TBL] [Abstract][Full Text] [Related]
5. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study. Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386 [TBL] [Abstract][Full Text] [Related]
6. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329 [TBL] [Abstract][Full Text] [Related]
7. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753 [TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964 [TBL] [Abstract][Full Text] [Related]
9. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study. Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057 [TBL] [Abstract][Full Text] [Related]
10. Thalidomide for the treatment of patients with myelodysplastic syndromes. Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256 [TBL] [Abstract][Full Text] [Related]
12. Low-dose Ara-C in myelodysplastic syndromes and acute nonlymphoid leukemia. Experience with seven patients. Bruzzese L; Abbadessa A; Ottaiano L; Arcidiacone G Haematol Blood Transfus; 1987; 30():315-21. PubMed ID: 3623239 [TBL] [Abstract][Full Text] [Related]
13. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB). Omine M; Yamauchi H Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575 [TBL] [Abstract][Full Text] [Related]
15. [A combination chemotherapy with cytarabine ocfosfate, low dose etoposide, and G-CSF for the treatment of high risk MDS (RAEB, RAEBt)--a pilot study]. Hara M; Kojima K; Azuma T; Narumi H; Shinagawa K Rinsho Ketsueki; 1998 Apr; 39(4):314-6. PubMed ID: 9597900 [TBL] [Abstract][Full Text] [Related]
16. [Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate]. Takeuchi M; Kojima K; Takaba S; Isokawa M; Tanimizu M; Kimura F; Ohmoto E; Harada M Gan To Kagaku Ryoho; 1995 Jan; 22(1):141-4. PubMed ID: 7826071 [TBL] [Abstract][Full Text] [Related]